| Species |
Human |
| Protein Construction |
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer[ Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and LMLGEFLKL peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&LMLGEFLKL |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer, His & Avi, Human at 0.5μg/ml (100μl/well) on the plate can bind Anti-B2M Antibody, mFc Tag.Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.5 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 53-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. |
| Synonyms |
Survivin; MHC; MHC I; BIRC5; API4; EPR-1; IAP4; survivin variant 3 alpha |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
